Advertisement

European Journal of Nuclear Medicine

, Volume 24, Issue 6, pp 615–620 | Cite as

Preliminary assessment of fluorine-18 fluorodeoxyglucose positron mission tomography in patients with bladder cancer

  • Shigeru Kosuda
  • Paul V. Kison
  • Robert Greenough
  • H. Barton Grossman
  • Richard L. Wahl
Original Article

Abstract

The purpose of this study was to assess the feasibility of imaging of bladder cancer with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scanning. We studied 12 patients with histologically proven bladder cancer who had undergone surgical procedures and/or radiotherapy. Retrograde irrigation of the urinary bladder with 1000–3710 ml saline was performed during nine of the studies. Dynamic and static PET images were obtained, and standardized uptake value images were reconstructed. FDG-PET scanning was true-positive in eight patients (66.7%), but false-negative in four (33.3%). Of 20 organs with tumor mass lesions confirmed pathologically or clinically, 16 (80%) were detected by FDG-PET scanning. FDG-PET scanning detected all of 17 distant metastatic lesions and two of three proven regional lymph node metastases. FDG-PET was also capable of differentiating viable recurrent bladder cancer from radiation-induced alterations in two patients. In conclusion, these preliminary data indicate the feasibility of FDG-PET imaging in patients with bladder cancer, although a major remaining pitfall is intense FDG accumulation in the urine.

Key words

Bladder cancer Fluorine-18 fluorodeoxyglucose Positron emission tomography 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Catalona WJ. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Stamey TA, Darracott Vaughan E, eds.Campbell's urology, 6th edn, vol 2. Philadelphia: Saunders; 1992: 1094–1158.Google Scholar
  2. 2.
    McCarthy P, Ramchandani P, Pollack H. The bladder and urethra. In: Vanel D, Stark D, eds.Imaging strategies in oncology. London: Martin Dunitz; 1993: 289–297.Google Scholar
  3. 3.
    Nurmi M, Katevuo K, Puntala P. Reliability of CT in preoperative evaluation of bladder carcinoma.Scand J Urol Nephrol 1988; 22: 125–128.Google Scholar
  4. 4.
    Lantz EJ, Hattery RR. Diagnostic imaging of urothelial cancer.Urol Clin North Am 1984; 11: 567–583.Google Scholar
  5. 5.
    Buy J-N, Moss A, Gulnet C, et al. MR staging of bladder carcinoma: correlation with pathologic findings.Radiology 1988; 169: 695–700.Google Scholar
  6. 6.
    Koraitim M, Kamal B, Metwalli N, Zaky Y. Transurethral ultrasonographic assessment of bladder carcinoma: its value and limitation.J. Urol 1995; 154: 375–378.Google Scholar
  7. 7.
    Schmidt JD, Weinstein SH. Pitfalls in clinical staging of bladder tumors.Urol Clin North Am 1976; 3: 107–127.Google Scholar
  8. 8.
    Wahl RL. Positron emission tomography: application in oncology. In: Murray IPC, Ell PJ, eds.Nuclear niedicine in clinicat diagnosis and treatment. Edinburgh: Churchill Livingstone; 1994: 801–882.Google Scholar
  9. 9.
    Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's disease.J Nucl Med 1995; 36: 1790–1796.Google Scholar
  10. 10.
    Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms.Cancer 1987; 60: 2682–2689.Google Scholar
  11. 11.
    Wahl RL, Cody RL, Hutchins GD, Kuhl DE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro2-deoxy-d-glucose.Radiology 1991; 179: 765–770.Google Scholar
  12. 12.
    Harney JV Wahl RL, Liebert M, et al. Uptake of 2-deoxy, 2-(18F)fluoro-d-glucose in bladder cancer: animal localization and initial patient positron emission tomography.J Urol 1991; 145: 279–283.Google Scholar
  13. 13.
    Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-d-glucose.J Comput Assist Tomogr 1993; 17: 582–589.Google Scholar
  14. 14.
    Toorongian SA, Mulholland GK, Jewett DM, Bachelor MA, Kilbourn MR. Routine production of 2-deoxy-2-[18F]fluoro-d-glucose by direct nucleophilic exchange on a quarternary 4-aminopyridinium resin.Int J Rad Appl Instrum 1990; 17: 273–279.Google Scholar
  15. 15.
    Zasadney KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images.J Nucl Med 1996; 37: 371–374.Google Scholar
  16. 16.
    Kim B, Semelka RC, Aschner SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.Radiology 1994; 193: 239–245.Google Scholar
  17. 17.
    Barentsz JO, Jager G, Mugler III JP, et al. Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences.AJR 1995; 164: 109–115.Google Scholar
  18. 18.
    Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.J Nucl Med 1993; 34: 414–419.Google Scholar
  19. 19.
    Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron tomography with18fluorine-labeled deoxyglucose.J Urol 1996; 155: 994–998.Google Scholar
  20. 20.
    Gallagher BM, Ansari A, Atkins H, et al. Radiopharmaceuticals XXVII.18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals.J Nucl Med 1977: 18: 990–996.Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Shigeru Kosuda
    • 1
  • Paul V. Kison
    • 1
  • Robert Greenough
    • 1
  • H. Barton Grossman
    • 2
  • Richard L. Wahl
    • 1
  1. 1.Department of Internal Medicine, Division of Nuclear MedicineThe University of Michigan Medical CenterAnn ArborUSA
  2. 2.Department of Urology and Cell BiologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations